PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryCurrent TOCInstructions for authors
 
J Neurol Neurosurg Psychiatry. Oct 1991; 54(10): 870–872.
PMCID: PMC1014569
The apomorphine test in parkinsonian syndromes.
D F D'Costa, R J Abbott, I F Pye, and P A Millac
Department of Neurology, Leicester Royal Infirmary, UK.
Abstract
The dopamine receptor agonist apomorphine has been used successfully to treat on-off swings in Parkinson's disease. Its value as a predictor of dopa responsiveness in idiopathic Parkinson's disease (IPD) was assessed and its potential role in differentiating IPD from the Parkinsonian plus syndromes (PPS) of multisystem atrophy, progressive supranuclear palsy and olivopontocerebellar atrophy was investigated. The response to an injection of apomorphine was observed in 20 patients with IPD and eight with PPS after being off levodopa for 12 hours. Patients were reassessed after taking levodopa for one month. Nineteen of the 20 patients (95%) with IPD showed a positive response to apomorphine and 18 (90%) to oral levodopa. In the PPS group, two patients (25%) responded to the apomorphine injection but not to oral levodopa. Apomorphine produced severe drowsiness in the PPS patients. It is suggested that the test can predict dopa responsiveness in IPD and may be of help in confirming a doubtful diagnosis. It has potential value in differentiating IPD from PPS.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (607K), or click on a page image below to browse page by page.
Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of
BMJ Group